Tag: AXS-12

All

Axsome to Submit New Drug Application for Narcolepsy Treatment AXS-12

The upcoming submission for AXS-12 (reboxetine) for cataplexy in narcolepsy follows supportive feedback from the FDA.

Axsome’s 2024 Results Show Growth in Sunosi Sales and Progress for AXS-12
Investigational AXS-12 Reduces Cataplexy in Narcolepsy Patients
Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3
Axsome to Present Data on AXS-12 and Solriamfetol at Sleep Europe 2024
Axsome Presents Positive Q1 Results, Advances in Sleep Medicine Pipeline
AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial

All

Axsome Eyes Phase 3 Trial Milestones for Sleep Disorder Drug Candidates in 2024

Axsome Therapeutics details anticipated milestones for investigational drugs for narcolepsy and excessive daytime sleepiness associated with shift work disorder.

Axsome Highlights Q3 Advancements in Sleep Disorder Treatment
Axsome to Initiate Phase 3 Study of Solriamfetol for Shift Work Disorder
Axsome’s Sunosi Sees Strong Growth in Prescription Numbers
Axsome Offers Updates on Sunosi and AXS-12
Axsome Begins Phase 3 Trial for Narcolepsy Drug Candidate
Axsome Expedites Development of Potential Narcolepsy Drug Based on FDA Breakthrough Therapy Meeting
Axsome’s Investigational Narcolepsy Compound Gets FDA Breakthrough Therapy Designation

All

Sorry, No Posts Found

Axsome Therapeutics’ AXS-12 Achieves Primary Endpoint in Phase 2 Trial in Narcolepsy

Dec 11, 2019 | Emerging Compounds, Narcolepsy

Axsome Therapeutics Inc announced that AXS-12 (reboxetine) met the prespecified primary endpoint and significantly reduced the number of cataplexy attacks as compared to placebo in patients with narcolepsy in the CONCERT Phase 2...

Tag: AXS-12

All

Axsome to Submit New Drug Application for Narcolepsy Treatment AXS-12

Axsome’s 2024 Results Show Growth in Sunosi Sales and Progress for AXS-12

Investigational AXS-12 Reduces Cataplexy in Narcolepsy Patients

Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3

Axsome to Present Data on AXS-12 and Solriamfetol at Sleep Europe 2024

Axsome Presents Positive Q1 Results, Advances in Sleep Medicine Pipeline

AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial

All

Axsome Eyes Phase 3 Trial Milestones for Sleep Disorder Drug Candidates in 2024

Axsome Highlights Q3 Advancements in Sleep Disorder Treatment

Axsome to Initiate Phase 3 Study of Solriamfetol for Shift Work Disorder

Axsome’s Sunosi Sees Strong Growth in Prescription Numbers

Axsome Offers Updates on Sunosi and AXS-12

Axsome Begins Phase 3 Trial for Narcolepsy Drug Candidate

Axsome Expedites Development of Potential Narcolepsy Drug Based on FDA Breakthrough Therapy Meeting

Axsome’s Investigational Narcolepsy Compound Gets FDA Breakthrough Therapy Designation

All

Sorry, No Posts Found

Axsome Therapeutics’ AXS-12 Achieves Primary Endpoint in Phase 2 Trial in Narcolepsy

Sleep Review

Our Parent Company

Key Resources

Helpful Links